Drug intelligence / Profile preview

ZIKVV

Development stage: Unknown
Lead developer: Vyro Bio
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies
Administration: Intramuscular

Overview

ZIKVV is a viral vector-based vaccine and gene therapy candidate developed by Vyro Bio for the prevention of Zika virus infection. The asset utilizes a modified viral vector platform to deliver genetic material encoding Zika virus antigens, aiming to stimulate a robust and protective immune response in recipients. According to Vyro Bio's corporate pipeline, ZIKVV is currently in Phase 1 clinical development, representing a key program in the company's infectious disease portfolio alongside its oncolytic virus candidates for central nervous system tumors.

Other names: ZIKVVZika virus vaccine

Beyond the preview

Go deeper on ZIKVV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZIKVV.

Explore the full profile